Antidepressants are typically one of the most costly drug classes in the dr
ug budget. Due to the higher costs of many of the newer antidepressants, a
number of studies have been conducted to evaluate the clinical and cost asp
ects of depression treatment. The purpose of this month's Practical Pharmac
oeconomics column is to assist readers in interpreting a cost-effectiveness
evaluation of antidepressant drugs that used a decision tree model to asse
ss the treatment of major depression.